longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Aurinia Pharma

AUPH

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 6.71, below the reasonable range, cheaper than 80.53% of the time in the past 1 years, and the industry ranks 24/602, the industry Median -2.12.

6.71xP/E
$15.83Stock price
$2.36Earnings per share
6.71xP/E
Stock price$15.83Earnings per share$2.36

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
7.26x
Typical range
6.71x–25.70x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
INCYUSIncyte
14.49x66.70%$23.37B
GRFSUSGRIFOLS SA
9.58x42.44%$5.03B
ACADUSAcadia Pharma
9.03x73.45%$3.44B
PURRUSHyperliquid Strategies
9.18x84.74%$2.35B
ADMAUSAdma Biologics
12.89x35.42%$2.18B
AUPHUSAurinia Pharma
6.71x54.40%$2.11B
LKFTUSLakefront Biotherapeutics
2.76x86.19%$1.91B
ANABUSAnaptysbio
5.54x1,003.56%$1.45B
VORUSVor BioPharma
1.76x89.77%$1.11B
MGTXUSMeiraGTx
13.12x122.03%$1.04B
ABUSUSArbutus Pharma
5.73x533.09%$876.38M
RIGLUSRigel Pharma
2.74x83.91%$880.76M
BVNRYUSBavarian Nordic A/S
3.42x--$820.28M
IRWDUSIronwood Pharma
4.63x715.55%$601.47M
AGENUSAgenus
4.10x--$376.37M
CUVLUSClinuvel Pharmaceuticals
13.27x--$304.08M
QTTBUSQ32 Bio
7.25x162.67%$245.00M
CGENUSCompugen
6.22x173.68%$218.81M
PLXUSProtalix Biotherap
11.53x400.00%$218.35M
VXRTUSVaxart
2.75x328.57%$106.28M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.